Abstract: A transcatheter prosthetic heart valve includes a stent frame and a leaflet material. The stent frame includes a top portion and a bottom portion. The leaflet material includes a lower portion attached to the stent frame and an upper portion that includes leaflets capable of moving between an open configuration and a closed configuration. At least a portion of the leaflet material weaves through the stent frame. The transcatheter prosthetic heart valve also includes one or more reinforcement components coupled to the stent frame and/or to the leaflet material to enhance performance of the transcatheter heart valve.

Abstract: A method of planning for an education with the assistance of a single source includes a user communicating with the single source for planning for multiple financial needs for an education, determining various insurance protection plans which are provided by the single source, selecting financing options for the education which are provided by the single source, obtaining spending tools which are provided by the single source, and procuring communications tools which are provided by the single source.

Abstract: Highly oil-filled ethylene/alpha-olefin/diene (EAODM) polymers in a free flowing powder or pellet form, processes for preparing these polymers, and the use of these polymers to prepare thermoplastic vulcanizates (TPV) are provided. Thermoplastic vulcanizate premixes can be prepared with the EAODM polymers and thermoplastic polymers, the premixes being easily converted into TPVs.

Abstract: Highly oil-filled ethylene/alpha-olefin/diene (EAODM) polymers in a free flowing powder or pellet form, processes for preparing these polymers, and the use of these polymers to prepare thermoplastic vulcanizates (TPV) are provided. Thermoplastic vulcanizate premixes can be prepared with the EAODM polymers and thermoplastic polymers, the premixes being easily converted into TPVs.

Abstract: A series of novel, melt- or mold-processable HA esters with varying aliphatic chain lengths are synthesized from silyl (HA-quaternary (quat.) ammonium salt complex (preferably silyl HA-CTA, a silylated HA complex with cetyltrimethyl ammonium salt). Introduction of aliphatic acyl groups, preferably acid chlorides, to disrupt the strong HA intermolecular bonding, is done via acylation. Acylation takes place at the oxygen of the trimethylsilyloxy group -0-Si(CH3)3 in the silyl HA-CTA by removal of trimethylsilyl. groups therefrom. Optionally, crosslinking may be performed during the shaping/molding of the HA esters into a structure/device, or thereafter, if at all. Native HA can then be regenerated/recovered by saponification/hydrolysis, removing acyl groups, —CH3(CH2)10CO, and the cetyltrimethyl ammonium salt groups, —CTA, from HA ester. The structure/device of a preselected shape (e.g.

Abstract: Pathological binaural phase time delay (PBTD) asynchrony is measured at a variety of frequencies and speech stimuli to develop a BPTD profile for a subject. A corrective device (600, 1000) is designed to apply clinical PBTD to compensate for the subject's pathological BPTD. An electronic device (500) is used to measure the subject's ability to comprehend words at a variety of relative time delays between ears to estimate the ideal overall relative time delay. The optimal relative phase shift at a variety of frequencies is also measured. An electronic device (600) may be used to correct the pathological BPTD by delaying sound in different frequency bands differently to the target ear, according to the BPTD profile, or a passive filtered earplug (1000) may be used to correct smaller amounts of BPTD.

Abstract: Highly oil-filled ethylene/alpha-olefin/diene (EAODM) polymers in a free flowing powder or pellet form, processes for preparing these polymers, and the use of these polymers to prepare thermoplastic vulcanizates (TPV) are provided. Thermoplastic vulcanizate premixes can be prepared with the EAODM polymers and thermoplastic polymers, the premixes being easily converted into TPVs.

Abstract: Invented are improved solid dosage formulations of endo-N-(9-methyl-9-azabicyclo[3.3.1.]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride. Also invented is an imporved method of administering an anti-emeticly effective amount of the compound endo-N-(9-methyl-9-azabicyclo[3.3.1.]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride.

Abstract: Invented are improved multidose aqueous formulations of endo-N-(9-methyl-9-azabicyclo[3.3.1.]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride.

Abstract: Invented are improved multidose aqueous formulations of endo-N-(9-methyl-9-azabicyclo[3.3.1. ]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride.

Abstract: Invented are improved solid dosage formulations of endo-N-(9-methyl-9-azabicyclo[3.3.1.]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride. Also invented is an imporved method of administering an anti-emeticly effective amount of the compound endo-N-(9-methyl-9-azabicyclo[3.3.1.]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride.